Randy F. Sweis, MD

Randy F. Sweis, MD, explains future avenues for the investigation for XmAb819 in tumor types beyond renal cell carcinoma.

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Randy F. Sweis, MD, discusses potential toxicities and mitigation strategies associated with the bispecific T-cell engager XmAb819.

Randy F. Sweis, MD, explains the mechanism of action of the ENPP3/CD3–targeted bispecific T-cell engager XmAb819 in renal cell carcinoma.

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

Over the past 5 years, medical oncologists have witnessed the revolutionary impact of immunotherapy on patients with advanced urologic malignancies. Over the next 5 years, these therapies likely will similarly transform urologic surgical care.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the management of TKI-associated adverse events in kidney cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the frequency of immune-related adverse events (irAEs).

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Randy F. Sweis, MD, clinical instructor, University of Chicago Medicine, discusses the trend toward immunotherapy in the field of genitourinary malignancies.